Hecht Foundation’s commitment will continue and expand the current NCCAM funded Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study.
The goal of this PD study is to collect as much data as possible over a five-year period with the hope of finding dietary and lifestyle factors associated with a slower disease progression.
To participate in this study please email neuroresearch[at]bastyr[dot]edu
Multiple sclerosis is often said to be an incurable, progressive, and degenerative disease. It is our hypothesis that some of you do not, or will not, have a progressive disease. The goal of this MS study is to collect as much data as possible over a five-year period with the hope of fiding dietary and lifestyle factors associated with a slower disease progression.
The NIH/NCCAM funded a clinical trial for prostate cancer patients at Bastyr University/University of Washington’s Mushroom Cancer Research Center. The purpose of the study is to test the safety and tolerability of consuming the mushroom supplement, and to detect the modulation of their immune functions in laboratory assays
Parkinson's disease (PD) is considered a progressive and irreversible neurodegenerative disease. Current therapies improve disease symptoms, however none alter the underlying degenerative course. Research suggests the loss of brain glutathione, a powerful antioxidant, is one of the earliest changes to occur in the brain of PD patients and the magnitude of glutathione depletion parallels the severity of PD. This study will look at the use of intranasal glutathione in PD patients to determine safety, tolerability, and the impact on PD symptoms.
The Bastyr University/University of Washington PCCTR Oncomycology Research Center will investigate the immunologic and antitumor effects of Trametes versicolor (Tv) a traditional Chinese medicine medicinal mushroom, for use in the treatment of prostate cancer and breast cancer patients in the U.S
Clinical management of locally advanced breast cancer remains challenging as patients have a high risk for relapse, especially those patients whose tumors over-express the HER-2/neu (HER2+) oncogenic protein and have limited expression of estrogen receptors (ER-).
Parkinson's disease (PD) is considered a progressive and irreversible neurodegenerative disease. Current therapies improve disease symptoms, however none alter the underlying degenerative course.
This study compares the genomic response in those who receive homeopathic verum to those who receive a placebo.